[Intrathecal therapy with 1 500 UI of antitetanic serum and 1.5 g of intravenous metronidazole: prognosis of tetanus in hospitalized patients in Togo].
OBJECTIVE
To determine the effect on clinical progression and mortality during tetanus of intrathecal therapy with 1 500 IU of heterologous antitetanus serum administered with 1.5 g of intravenous metronidazole.


METHODS
This prospective study took place from August 1, 2006, to June 30, 2007, and included two groups of patients randomly allocated to treatment by two different techniques. The test group of 17 patients received 1 500 IU of antitetanus heterologous immunoglobulin by the intrathecal route as well as 1.5 g of intravenous metronidazole daily. The control group of 25 patients received the standard treatment of 9 000 IU of heterologous antitetanic serum administered half (4 500 IU) cutaneously and half intramuscularly. Clinical manifestations and mortality were assessed. Mollaret's classification and the Dakar prognosis score were used to classify patients according to severity.


RESULTS
Forty-two patients were treated. Their mean age was 29.44 years (standard deviation: 18.3 years) and the M/F sex ratio was 5. Skin wounds accounted for 57.1% of the portals of entry, deep wounds for 26.2%; the rest were unknown. Twenty patients (47.6%) had fever when admitted. Tetanus was generalized in all cases and 76.2% of patients were stage III. Four patients were HIV-positive. Clinical improvement, defined as a decrease in dysphagia, trismus, and paroxysm, was observed more quickly in the test group: 48 hours after treatment began, improvement was seen in more than 76% of the test group compared with 28% in the control group. In the test group, the mean hospitalization period was 7.4 days and mortality was 11.7%, compared with 19 days and a mortality rate of 52% in the control group.


CONCLUSIONS
Prevention through vaccination appears to be the long-term solution for the eradication of tetanus. In the meantime, we can hope for a better clinical response with intrathecal therapy of 1 500 IU of heterologous antitetanus serum and 1.5 g of intravenous metronidazole daily.
Wateba
Mi
M
Service des maladies infectieuses et de pneumologie Centre hospitalier universitaire de Tokoin BP 57 Lomé Togo. majeste7@yahoo.fr
Diop
Sa
S
Nichols
S
S
Patassi
A
A
Adjo
S
S
Gbadamassi
G
G
Tidjani
O
O
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007278:Injections, Spinal; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage*; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D013742:Tetanus / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D013743:Tetanus Antitoxin / Q000008:administration & dosage*; D014037:Togo; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D013743:Tetanus Antitoxin; D008795:Metronidazole